CytoTools
Market Cap
€30.8m
Last Updated
2020/01/18 21:03 UTC
Data Sources
Company Financials +
Executive Summary
CytoTools AG, a biotechnology company, develops a pipeline of disease modifying therapies.
Rewards
Risk Analysis
Snowflake Analysis
Mediocre balance sheet and slightly overvalued.
Share Price & News
How has CytoTools's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: T5O has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
7.5%
T5O
-8.1%
DE Biotechs
0.06%
DE Market
1 Year Return
56.0%
T5O
5.9%
DE Biotechs
14.8%
DE Market
Return vs Industry: T5O exceeded the German Biotechs industry which returned 5.3% over the past year.
Return vs Market: T5O exceeded the German Market which returned 17.1% over the past year.
Shareholder returns
| T5O | Industry | Market | |
|---|---|---|---|
| 7 Day | 7.5% | -8.1% | 0.06% |
| 30 Day | 14.7% | -1.8% | 1.8% |
| 90 Day | 12.3% | 11.4% | 7.1% |
| 1 Year | 56.0%56.0% | 6.1%5.9% | 18.4%14.8% |
| 3 Year | -0.7%-0.7% | 56.9%55.2% | 17.4%7.0% |
| 5 Year | -81.0%-81.0% | 16.4%13.9% | 27.9%10.4% |
Price Volatility Vs. Market
How volatile is CytoTools's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 year ago | Simply Wall St
Who Are CytoTools AG's (ETR:T5O) Major Shareholders?1 year ago | Simply Wall St
Does CytoTools AG's (ETR:T5O) Earnings Growth Make It An Outperformer?Valuation
Is CytoTools undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: T5O (€11.5) is trading below our estimate of fair value (€137.71)
Significantly Below Fair Value: T5O is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: Insufficient data to calculate T5O's PE Ratio to determine if it is good value compared to the Biotechs industry average.
PE vs Market: Insufficient data to calculate T5O's PE Ratio to determine if it is good value compared to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate T5O's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: Insufficient data to calculate T5O's PB Ratio to determine if it is good value.
Next Steps
Future Growth
How is CytoTools forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
38.9%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as CytoTools has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Next Steps
- Take a look at our analysis of T5O’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- CytoTools competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
Past Performance
How has CytoTools performed over the past 5 years?
22.4%
Historical Pharmaceuticals & Biotech annual earnings growth
Earnings and Revenue History
Quality Earnings: Insufficient data to determine if T5O has high quality earnings.
Growing Profit Margin: Insufficient data to determine if T5O's profit margins have improved over the past year.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if T5O's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare T5O's past year earnings growth to its 5-year average.
Earnings vs Industry: Insufficient data to determine if T5O's earnings growth over the past year exceeded the Biotechs industry average.
Return on Equity
High ROE: T5O has a negative Return on Equity (0%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is CytoTools's financial position?
In this section we usually analyse CytoTools's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. CytoTools has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.
Next Steps
- Take a look at our analysis of T5O’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. CytoTools's cash and debt levels may be found in its annual reports archived here.
- Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when CytoTools's financial data was last updated here.
- Explore more healthy companies in the Pharmaceuticals & Biotech industry.
Dividend
What is CytoTools's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate T5O's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate T5O's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if T5O's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if T5O's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of T5O's dividend in 3 years as they are not forecast to pay a notable one for the German market.
Next Steps
Management
What is the CEO of CytoTools's salary, the management and board of directors tenure and is there insider trading?
CEO
Mark-André Freyberg 0
20yrs
Tenure
Dr. Mark-André Freyberg co-founded CytoTools AG in 2000 and serves as Chief Executive Officer and Chairman of Management Board also served as its Managing Director. Dr. Freyberg served as the Head of Proje ...
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Insufficient data to determine if shareholders have been diluted in the past year.
Management Team
Mark-André Freyberg
Chairman of Management Board & CEO
- Tenure: 20yrs
Peter Friedl
Vice-Chairman of Management Board & Member of Supervisory Board
Dirk Kaiser
Co-Founder
Board Members
Peter Friedl
Vice-Chairman of Management Board & Member of Supervisory Board
Heiner Hoppmann (61yo)
Member of Supervisory Board
- Tenure: 2.4yrs
Manfred May
Chairman of Supervisory Board
Herr Hoffmann
Member of Supervisory Board
Bernhard Seehaus
Member of Supervisory Board
Ruediger Weseloh
Member of Supervisory Board
Company Information
CytoTools AG's company bio, employee growth, exchange listings and data sources
Key Information
- Name: CytoTools AG
- Ticker: T5O
- Exchange: XTRA
- Founded: 2000
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: €30.801m
- Shares outstanding: 2.69m
- Website: https://cytotools.de
Number of Employees
Location
- CytoTools AG
- Klappacher Strasse 126
- Darmstadt
- Hessen
- 64285
- Germany
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| T5O | DB (Deutsche Boerse AG) | Yes | Bearer Shares | DE | EUR | Dec 2006 |
| T5O | XTRA (XETRA Trading Platform) | Yes | Bearer Shares | DE | EUR | Dec 2006 |
| T5OD | BATS-CHIXE (BATS 'Chi-X Europe') | Yes | Bearer Shares | GB | EUR | Dec 2006 |
Biography
CytoTools AG, a biotechnology company, develops a pipeline of disease modifying therapies. The company’s therapies include proprietary small molecules and biologics to provide treatment options in dermatology, cardiology and angiology, urology, and oncology. Its lead clinical product is DermaPro that has completed Phase III clinical trials for the treatment of diabetic foot ulcers in India; is in Phase III clinical trials for diabetic foot ulcer treatment in Europe; and is in Phase II/III clinical studies for the treatment of venous leg ulcers in Germany, as well as is used as an anti-infective. The company also develops Utisept, an urological medical device for flushing the bladder in urinary tract infections; Derma MP for the treatment of venous leg ulcers in Europe; CardioClean that is in preclinical stage for the treatment of restenosis, diabetis, and carotis-stenosis; and Cancer T17-n for cancer treatment in Europe. CytoTools AG was founded in 2000 and is based in Darmstadt, Germany.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/01/18 21:03 |
| End of Day Share Price | 2020/01/17 00:00 |
| Earnings | 2018/06/30 |
| Annual Earnings | 2017/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.